WHITE PAPER

The Doctor's Nudge:

How Physician-Led Patient Education Drives Therapy Starts and Long-Term Adherence

A comprehensive review of clinical, behavioral, and marketing evidence supporting physician education as a primary lever for improving therapy initiation and adherence in complex disease states.

March 2026 | For Internal Use and Discussion

Executive Summary

Medication non-initiation and non-adherence represent one of the most costly and preventable failures in modern healthcare. In the United States alone, roughly one in four new prescriptions is abandoned before a patient ever picks it up, and the cumulative cost of non-adherence to the healthcare system exceeds $672 billion annually. For complex therapies in oncology, immunology, neurology, and psychiatry, these numbers are even more alarming: abandonment rates for oral anticancer medications routinely exceed 18%, and non-adherence frequently triggers preventable relapses, hospitalizations, and disease progression.

This white paper assembles converging evidence from clinical trials, meta-analyses, behavioral psychology, and marketing research to make a single, data-supported argument:

> *The physician-patient educational encounter — whether at the point of prescribing, in the clinic, or extended into the home — is the most powerful, scalable, and underutilized intervention available to improve both therapy starts and long-term adherence.*

The evidence base is substantial. A landmark meta-analysis of 127 studies found that patients of physicians who communicate well are 19% more likely to adhere to treatment, and that training physicians in communication skills raises the odds of adherence by a factor of 1.62. A 2022 field study published in the Journal of Medical Internet Research demonstrated that physician-patient communication explains 69.3% of the variance in actual patient adherence behavior — making it the single largest explanatory variable identified in the literature. The PRELAPSE study in psychiatry found that 91% of patients accepted complex injectable therapy when the prescribing physician led a structured educational conversation. In oncology, medically integrated pharmacy models — where physician and pharmacy teams educate patients together at the point of care — reduced oral anticancer medication abandonment from a national average of 18% to less than 1%.

Marketing and behavioral science amplify these clinical findings. Physicians remain the most trusted source of health information. Drawing on the Theory of Planned Behavior, research shows that physician-built trust creates a direct pathway from information to intent to action — the behavioral triad required for therapy initiation. Academic detailing studies demonstrate that structured physician education changes prescribing and patient communication behavior in ways that persist for at least nine months after a single intervention.

The implications are clear: investments in physician education programs — at the point of prescribing and extended digitally or in-person into the home — represent a high-yield strategy for any stakeholder seeking to reduce abandonment, increase therapy start rates, and sustain long-term adherence in complex disease states.

Section 1: The Scale of the Problem — Non-Initiation and Non-Adherence

1.1 Abandonment Before the First Fill

The journey from a written prescription to an ingested first dose is far longer and more fraught than most healthcare stakeholders recognize. Research from Brigham and Women's Hospital and CVS Caremark established that approximately 25% of all new prescriptions are abandoned at the pharmacy — never filled, never started. IQVIA's 2020 national analysis confirmed that 9% of new prescriptions written at retail pharmacies were abandoned, a figure that undercounts the full scope because it excludes prescriptions never sent to pharmacy at all.

[1][2]

~25%
of new prescriptions abandoned before first fill (Brigham & Women's)

$672B
annual U.S. cost of medication non-adherence (estimated, all causes)

18%
average abandonment rate for oral oncology medications nationally

1.2 The Cost-Abandonment Relationship

Out-of-pocket cost is the most potent single predictor of whether a patient will abandon a prescription. The data from the Brigham and Women's / CVS Caremark research is unambiguous: at zero cost-sharing, abandonment rates are approximately 5%. At $50 out-of-pocket, patients are nearly four times more likely to abandon than those paying $10. When cost-sharing exceeds $125, abandonment approaches 45%. This relationship is particularly acute for specialty and biologic therapies, where list prices routinely generate high patient cost exposure absent adequate financial support.

[1]



Figure 1. Prescription Abandonment Rate by Patient Out-of-Pocket Cost at Pharmacy

> *Key Insight: Cost is a primary driver of abandonment — but the research is clear that patients are also abandoning prescriptions due to lack of knowledge about the medication's necessity, complexity of administration, and fear of side effects. These are educational gaps that can be closed by the prescribing physician.*

1.3 The Ongoing Adherence Crisis

Even among patients who successfully start therapy, sustained adherence remains a profound challenge. The World Health Organization has estimated that among patients with chronic diseases, only 50% adhere to prescribed medication regimens in developed countries. Non-adherence drives 12 million hospitalizations annually in the United States and is implicated in more than 125,000 preventable deaths each year.

[25][6]

For specialty and complex medications, the adherence challenge is compounded by unique barriers: self-injection requirements, intensive safety monitoring, frequent follow-up visits, limited distribution networks, and the psychological weight of receiving a serious diagnosis. These factors underscore why the educational scaffolding provided by the prescribing physician — both at initiation and throughout the treatment journey — is not a nice-to-have, but a clinical necessity.

Section 2: The Physician as Primary Educator and Trust Anchor

2.1 Physicians Remain the Most Trusted Health Information Source

In an era of abundant — and often conflicting — health information, the physician stands as the primary, most trusted arbiter of what a patient believes and does. Research consistently confirms that, despite the rise of online health resources and social media, physicians are rated as the most credible source of health information by patients across all demographics. This credibility is not merely positional; it is earned through the relationship, and it creates a unique leverage point.

[26][5]

> *"Relationships as medicine: quality of the physician-patient relationship determines physician influence on treatment recommendation adherence." — Orom et al., Journal of the American Board of Family Medicine, 2018*

2.2 The Behavioral Pathway: From Trust to Adherence

A 2022 field study published in the Journal of Medical Internet Research applied the Theory of Planned Behavior (TPB) to model how physician communication creates downstream adherence behavior. The study found that physician communication significantly increases patient trust in their physician. That trust, in turn, shapes patient attitude toward the treatment, which drives behavioral intention, and ultimately produces actual adherence behavior. The model explained 69.3% of the variance in actual patient adherence — an exceptionally high explanatory power for a behavioral model in healthcare.

[5]



Figure 2. Behavioral Pathway: Physician Education → Patient Trust → Therapy Start & Adherence (TPB Model)

The TPB framework helps explain why the physician's educational role is so powerful: unlike a brochure, an app notification, or a pharmacy technician's brief, the physician's recommendation carries relational authority. It activates not just the informational but the motivational circuits of decision-making. Patients want to follow through on commitments made to their physician.

2.3 Trust as a Behavioral Economics Variable

From a marketing and behavioral science perspective, physician trust functions as what behavioral economists call a "credibility cue" — a signal that dramatically lowers the cognitive effort required for a patient to accept and act on a recommendation. Research in health psychology consistently shows that passive decision-makers (the plurality of patients, particularly those newly diagnosed with serious illnesses) are highly susceptible to physician recommendation acceptance. When patients are uncertain, anxious, or overwhelmed — conditions that define most specialty therapy initiation scenarios — they default to the judgment of their trusted physician.

[26][5]

This insight has direct strategic implications: the physician's recommendation, delivered with confidence and backed by an educational conversation that addresses the patient's specific concerns, is the highest-conversion "marketing message" available. No patient support program, co-pay card, or digital engagement tool can replicate the trust-weighted authority of a physician saying, "I want you on this therapy, and here is why it matters."

Section 3: Evidence on Therapy Starts — From Prescription to First Fill

3.1 The Medically Integrated Pharmacy Model: The Most Compelling Data

The clearest demonstration of what physician engagement can achieve at the point of prescribing comes from the Medically Integrated Pharmacy (MIP) model studied at Texas Oncology and published in JCO Oncology Practice. In this model, clinical pharmacy teams work alongside oncologists as an integrated part of the care team, providing structured patient education, financial navigation, and prior authorization support at the point of prescribing — before the patient ever reaches a retail pharmacy counter.

[7]

The results were striking: despite 29% of patients having a documented financial barrier to therapy, the abandonment rate within the MIP model was less than 1%. The national average for the same oral anticancer medications is approximately 18%. This 17+ percentage point gap in start rates is attributable directly to the intervention at the point of prescribing — the educational, financial, and logistical support provided before the patient left the clinic.



Figure 3. Therapy Start Rates by Care Model — Standard vs. Physician-Integrated Approaches

> *The MIP data represents perhaps the strongest available evidence that a structured physician-anchored education and support intervention at the point of prescribing can reduce oral oncology abandonment from 18% to under 1% — even in a population with high documented financial burden.*

3.2 Real-Time Prescription Benefits and the Prescriber Conversation

A complementary lever for improving start rates is the integration of real-time prescription benefit (RTPB) tools into EHR workflows. When these tools surface a patient's out-of-pocket

cost estimate at the moment of prescribing, they create the conditions for the physician to have a cost conversation before the patient is standing alone at the pharmacy counter. A study published in Research in Social and Administrative Pharmacy found that RTPB tools generated an average out-of-pocket savings of $38.83 per 30-day supply when prescribers accepted an alternative — and the most significant impact was seen with high-cost specialty drugs.

[9][8]

Critically, the mechanism of action here is the physician — the tool provides information, but it is the prescriber's willingness to engage the patient in a conversation about cost and alternatives that drives the outcome. The prescriber is the active ingredient.

3.3 Prior Authorization as an Educational and Advocacy Opportunity

A 2023 AMA survey found that 78% of physicians report prior authorizations at least sometimes lead to treatment abandonment, and 83% report the number of PAs required has increased over the past five years. The average time to complete a PA for a biologic or specialty medication ranges from days to weeks — a window during which uninformed or unsupported patients frequently disengage.

[12]

Physicians who proactively educate patients about the PA process — explaining that delays are administrative rather than a reflection of clinical necessity, setting clear expectations about timelines, and providing a point of contact for questions — measurably improve the rate at which patients remain engaged through the process and ultimately start their therapy. This is physician education functioning as a retention tool.

3.4 The Ambulatory Clinic-Pharmacy Collaboration Model

A study published in the Journal of the American College of Clinical Pharmacy examined a model where an ambulatory care pharmacy technician received a report of at-risk prescriptions and conducted proactive patient outreach to address insurance issues, prior authorization barriers, and informational gaps before patients reached the pharmacy. The program was physician-initiated and structured around the prescribing encounter.

[10]

The study found that proactive intervention in the window between prescribing and first fill — the window that physician education is best positioned to open — was directly associated with reduced prescription abandonment. Barriers addressed included incorrect insurance information, need for prior authorization, and lack of patient awareness about next steps.

Section 4: Evidence on Long-Term Adherence — Communication, Trust, and Shared Decision-Making

4.1 The Communication-Adherence Meta-Analysis (127 Studies)

The foundational quantitative evidence for the physician communication-adherence link comes from a landmark meta-analysis by Zolnierek and DiMatteo, published in Medical Care in 2009. Drawing on 127 studies and tens of thousands of patient observations, the analysis reached two conclusions that have shaped the field:

[3]

- Patients of physicians who communicate well have a 19% higher rate of adherence compared to patients of physicians who communicate poorly.
- Training physicians in communication skills raises the odds of patient adherence by a factor of 1.62 — meaning patients are 62% more likely to adhere when their physician has received communication training.

The effect sizes are clinically meaningful. A 19% improvement in adherence rates for a specialty therapy with a national adherence baseline of 65% translates to a 12-point gain — shifting patients from inadequate to adequate adherence thresholds in many disease states.



Figure 4. Patient Adherence Rate by Level of Physician Communication and Education Intervention

4.2 Provider-Targeted Intervention Effect Sizes

A systematic review and meta-analysis published in BMC Health Services Research examined 218 reports covering 151,182 subjects and calculated effect sizes for provider-targeted adherence interventions. The mean difference effect size was 0.233 — statistically robust and

comparable to effect sizes seen for pharmacological interventions in comparable chronic disease adherence literature.

[17]

Notably, the review found no significant difference in effect size based on whether the provider was a physician (0.227), nurse (0.230), or pharmacist (0.249), suggesting that the key active ingredient is the trusted provider relationship and structured educational engagement — not the specific credential of the provider. This finding is highly relevant for designing scalable physician education programs that leverage the broader care team.

4.3 RCT Evidence: +14.1% Adherence Over Standard Care

A systematic review of 79 randomized controlled trials, measuring adherence outcomes via electronically compiled drug dosing histories, found that patients randomized to an adherence intervention showed outcomes that were, on average, 14.1% higher than patients in standard care control groups. The review confirmed that multi-component interventions — combining patient education, behavioral support, and follow-up — consistently outperformed single-component approaches.

[20][4]

> *Synthesis finding from systematic review: "A systematic review revealed that single interventions were often insufficient to improve medication adherence, and the use of multiple interventions had become increasingly common as it was considered more effective in maximizing adherence improvement programs." (Kaniuka et al., 2025)*

4.4 Shared Decision-Making as an Adherence Multiplier

Shared decision-making (SDM) — in which the physician actively involves the patient in selecting a treatment approach based on their values and preferences — represents the most sophisticated form of point-of-prescribing physician education. The evidence for its effect on adherence is now substantial:

[18][14][19]

- A systematic review of eleven RCTs found that five showed positive effects of SDM on adherence, with the balance showing equivalent or time-delayed benefits.
- In multiple sclerosis, patients who experienced SDM at disease-modifying therapy (DMT) initiation showed significantly higher adherence to complex biologic and oral DMTs.
- The ANANAS study in COPD and asthma found that SDM was associated with improved adherence to inhalation medications — a class notorious for technique errors and early discontinuation.
- Across disease states, the consistent finding is that patients who feel heard and whose preferences are incorporated into the treatment plan are more motivated and more adherent.

4.5 The Patient Knowledge Effect

A meta-analysis of patient-centered outcomes from adherence interventions found a statistically significant standardized mean difference for medication knowledge of d = 0.449 — indicating that educational interventions meaningfully increase what patients know and understand about their therapy. Importantly, increased knowledge was associated with improvements in quality of life (d = 0.127), physical function (d = 0.142), and symptoms (d = 0.182).
[23]

This finding is particularly important for complex specialty therapies, where patient misunderstanding of mechanism, expected timeline to effect, and side effect management is a primary driver of early discontinuation. The physician's educational role is to bridge the gap between clinical knowledge and patient understanding — and the data shows that when this bridge is built, patients stay on therapy.

Section 5: Disease-Specific Evidence

5.1 Oncology — Oral Cancer Therapies

Oral oncology agents have a particularly acute adherence challenge because they shift the treatment burden from the infusion center (where compliance is ensured by clinical proximity) to the home. A cluster-randomized controlled trial published in Supportive Care in Cancer evaluated a standardized patient education program delivered by physicians and oncology nurses at therapy initiation. The program addressed side effect management, dose modification protocols, and the importance of consistent adherence. The trial found a significant reduction in unplanned therapy interruptions in the intervention group — a direct measure of adherence failure avoided through education.

[15][7]

> *Texas Oncology MIP Study: With physician-integrated pharmacy education at the point of prescribing, oral anticancer medication abandonment fell from a national average of 18% to less than 1% — even in a patient population where 29% had a documented financial barrier.*

5.2 Multiple Sclerosis — Disease-Modifying Therapies

The MS DMT literature offers some of the most rigorous evidence for physician education effects on both starts and adherence. American Academy of Neurology (AAN) guidelines explicitly call on clinicians to "evaluate readiness or reluctance to initiate DMT and counsel on its importance" — recognizing counseling at prescribing as a core clinical competency, not a supplement.

[21][14][22]

Observational data from the MSBase and Swedish MS registries found that patients whose physicians initiated high-efficacy therapy within 2 years of diagnosis had a 66% lower risk of disability progression after 6 to 10 years compared to patients who started later. This gap is not entirely explained by biological factors — it reflects, in part, how effectively physicians communicated urgency, benefit, and the value of early action to their patients.

A study examining SDM and DMT adherence found that patients new to DMT therapy had significantly higher adherence odds when they had engaged in a collaborative prescribing decision with their neurologist — including video consultations with specialty pharmacists embedded in the process.

5.3 Psychiatry — Long-Acting Injectable Antipsychotics

The PRELAPSE study examined whether structured physician education about the benefits of long-acting injectable (LAI) antipsychotics — combined with SDM and communication training — could improve acceptance and adherence in patients with schizophrenia, a population with notoriously high non-adherence rates. Clinicians attended training focused on the importance of LAIs, shared decision-making strategies, and communication techniques.

[13]

The result: 91% of patients included in the study accepted LAI therapy when it was proposed by a physician who had received the education and communication training — a dramatic improvement over historical rates and a powerful demonstration that physician education changes both the clinician's behavior and the patient's response.

5.4 Rheumatology — Biologic and DMARD Therapies

A randomized controlled trial published in PMC evaluated the effect of structured patient education on medication adherence in patients with rheumatoid arthritis initiating DMARD therapy. After 12 weeks, adherence rates increased significantly in both single-intervention and multi-component education groups, with multi-component groups achieving mean adherence of 97.6%. The study found that education alone — delivered in the clinical setting by providers — was sufficient to produce meaningful adherence improvements.

[24]

Section 6: The Marketing and Behavioral Science Case

6.1 The Physician as the Highest-Yield Education Channel

From a health marketing perspective, the physician is not merely one channel among many for reaching patients — the physician is the channel with the highest conversion potential. A patient who receives a recommendation from their physician operates under a fundamentally different decision calculus than a patient who receives information from an advertisement, a patient support program call, or an app notification. The physician's recommendation carries social contract weight: it implies personal accountability, reflects individualized clinical assessment, and leverages a trusted relationship built over time.

[26]

Research from health services marketing confirms that physicians are the most important influence on patient treatment decisions and the most trusted source of medication-related information. Survey data consistently shows that patients are far more likely to act on information from their physician than from any other source — including friends, family, online resources, or pharmaceutical materials.

6.2 Academic Detailing — Educating the Educator

A foundational study by Avorn and Soumerai, published in the New England Journal of Medicine in 1983 and since replicated many times, examined what happens when clinical pharmacists conduct structured, face-to-face educational outreach with physicians — a model now known as academic detailing. The original trial found a 14% reduction in targeted prescribing patterns, with no significant effect from printed educational materials alone, and effects persisting for at least nine months after a single educational visit.

[16]

The academic detailing literature is relevant here because it demonstrates that physicians are themselves learnable and changeable through structured education. If educating physicians changes their prescribing and communication behavior — and if changed physician communication behavior demonstrably improves patient starts and adherence — then investing in physician education programs represents a compounding, high-yield strategy.

> *"Physician skill at communicating in the medical visit may be a central factor in achieving patient adherence because it improves the transmission and retrieval of important clinical and psychosocial information, facilitates patient involvement in decision making, allows open discussion of benefits, risks, and barriers to adherence, builds rapport and trust, and offers patients verbal and nonverbal support and encouragement." — Zolnierek & DiMatteo, Medical Care, 2009*

6.3 Behavioral Economics: Commitment, Anchoring, and Social Norms

Behavioral economics offers a complementary lens for understanding why physician education at the point of prescribing is so effective at driving therapy starts. Three mechanisms are particularly relevant:

Commitment Devices: When a patient verbally commits to a therapy in the presence of their physician, they are more likely to follow through — a well-documented principle in behavioral economics. Physician education that elicits a patient's verbal commitment ("I'll fill this prescription today") dramatically increases the probability of first-fill.

Anchoring and Framing: How a physician frames a therapy shapes a patient's baseline expectations. A physician who says "this medication will likely cause nausea for the first two weeks, which is normal and manageable" is setting an anchor that prevents the patient from interpreting early side effects as a reason to stop. Physician education is, in part, expectation management.

Social Norms and Peer Influence: Research in health psychology shows that when physicians communicate that "most patients in your situation start this therapy and do well," they are leveraging descriptive social norms to reduce patient resistance. This is a standard behavioral economics technique applied through the physician communication channel.

6.4 Information as the Active Ingredient for Complex Therapy Decisions

Unlike simple acute medications, complex specialty therapies require patients to process substantial information before and after initiation: administration technique, monitoring requirements, expected onset, side effect profiles, and what to do if problems arise. Research consistently shows that patients who do not receive adequate education at initiation are more likely to stop therapy at the first adverse experience — not because the experience was intolerable, but because it was unexpected.

[6][15]

Physician-led education at initiation serves as a prophylactic against this pattern. It transforms what would otherwise be a frightening and disorienting experience into an anticipated, normalized, and manageable one. The clinical and marketing insight are aligned: informed patients start, and informed patients stay.

Section 7: How Marketing Research Validates the Physician Education Model

The clinical and behavioral evidence for physician-led patient education does not stand alone. An extensive body of marketing research — encompassing direct-to-consumer advertising, patient activation science, social proof theory, social marketing, and pharmaceutical marketing psychology — independently corroborates the same central conclusion: targeted, credible, relationship-anchored communication drives patients to initiate and sustain treatment. This section examines what marketing science tells us about the mechanisms and levers of patient behavior change, and shows how physician-led education is, in marketing terms, the most effective channel available.

7.1 Direct-to-Consumer Advertising: What It Achieves — and Why Physicians Do It Better

Direct-to-consumer advertising (DTCA) is one of the most studied levers of patient treatment initiation. The U.S. and New Zealand are the only countries that permit DTCA for prescription drugs, making them a natural laboratory for studying advertising-driven treatment behavior. The data on DTCA's impact on therapy starts is unambiguous:

[28][29][30]

- A landmark study by Liu and Gupta (2023) found that exposure to pharmaceutical advertising led to large increases in treatment initiation and improved medication adherence, with sizeable positive spillover effects even for non-advertised generic drugs in the same class.
- In an FDA study of patient and physician attitudes toward DTCA, approximately one-third of patients reported that a DTC advertisement had generated a specific question for their physician — demonstrating the role of advertising in activating health-seeking behavior.
- Across DTCA-prompted physician conversations, prescribers reported prescribing the advertised drug in 39% of visits — a direct conversion metric that any marketing channel would envy.
- DTCA has been shown to increase the number of office visits for the advertised condition — meaning advertising does not merely shift demand, it creates new patient-system contact that would not otherwise have occurred.

The critical insight from the DTCA literature, however, is not simply that advertising works — it is why it works, and where its limits are. DTCA raises awareness, reduces stigma, and prompts patients to initiate conversations with their physicians. But the conversion event — the moment a patient commits to starting therapy — happens overwhelmingly inside the physician-patient relationship, not in the living room during a television commercial. Research consistently shows that patients act on DTCA primarily when it is subsequently endorsed and contextualized by their physician. The ad opens the door; the physician closes the sale.

[29][30]

> *Marketing Research Insight: DTC advertising is effective at generating patient awareness and prompting conversations — but the conversion to therapy initiation is mediated by the*

physician relationship. Physician education is both the endpoint and the amplifier of every upstream marketing investment.

7.2 Patient Activation Science: Measuring the Gap Between Awareness and Action

The Patient Activation Measure (PAM), developed by Hibbard et al. and validated across hundreds of thousands of patients, is the leading behavioral science instrument for quantifying a patient's readiness to engage in their own healthcare. PAM scores patients on a 0-to-100 scale across four stages: disengagement, early action, building skills, and maintaining behavior. The research on PAM outcomes is directly relevant to understanding how physician education drives therapy starts:

[31][32]

- Higher PAM scores at baseline are associated with nine of thirteen better health outcomes in large cohort studies, including better clinical indicators, more healthy behaviors, and improved medication adherence.
- When PAM levels increase over time, health outcomes and costs improve concurrently — establishing a causal link between activation and adherence.
- Patients at the lowest activation levels (Levels 1 and 2) are passive, easily overwhelmed by information, and highly susceptible to defaulting to inaction when facing a complex therapy decision. This is the population most at risk for prescription abandonment — and the population most responsive to physician-led educational engagement.

The PAM literature establishes a clear marketing problem: a substantial proportion of patients receiving new specialty therapy prescriptions are insufficiently activated to navigate the initiation process independently. They need an engagement intervention that meets them at their activation level, builds their confidence, and converts passive receipt of a prescription into active commitment to starting therapy. That intervention is the physician-led educational encounter.

[31]

1/3
of patients say a DTC ad generated a question for their doctor (FDA survey)

39%
of DTCA-prompted physician visits resulted in prescribing the advertised drug

41%
decline in 30-day readmissions when targeted text-message patient outreach campaigns were used

7.3 Learning from Marketing: Emotional Barriers Are the Primary Obstacle to Therapy Starts

A research study published in PMC — explicitly titled "Learning from Marketing" — applied consumer marketing research methodology to identify which messages most effectively drive patients to initiate recommended medications. The study used focus groups, message testing, and behavioral surveys with patients who had been prescribed but not yet started therapy for chronic conditions. The findings directly parallel best practices in pharmaceutical marketing and in physician-patient communication:

[33]

- The most persuasive messages were those that captured attention, overcame emotional barriers, and empowered patients to take action — not those that provided the most clinical information.
- Patients consistently reported that fear, uncertainty, and perceived complexity were the primary reasons they had not started therapy — not cost alone, and not lack of awareness.
- Messages framed around patient empowerment and personal agency significantly outperformed messages framed around clinical necessity or physician authority.
- The study concluded that this marketing-derived approach "has the potential to decrease undertreatment of chronic conditions" — meaning marketing research directly supports a patient education imperative.

These findings have a direct implication for physician education programs: the content and framing of what a physician says at the point of prescribing matters as much as the fact that they say it. Physicians trained to acknowledge and address emotional barriers — to say "I know this seems overwhelming, and here is what most patients experience in the first few weeks" — are applying proven marketing principles in a clinical context, with the added power of the physician-patient trust relationship amplifying every message.

[33][37]

7.4 Social Proof: The Most Powerful Behavioral Lever the Physician Can Deploy

Social proof — the tendency to look to the behavior of others as a guide for one's own actions, particularly in ambiguous or high-stakes situations — is one of the six foundational principles of influence identified by behavioral psychologist Robert Cialdini. In healthcare, social proof is a uniquely powerful force because patients facing a new, complex, or frightening treatment decision are precisely the type of actors most susceptible to social influence: they are uncertain, the stakes are high, and they are looking for any credible signal of what the "right" choice is.

[34][39]

What makes physician-delivered social proof uniquely powerful is the combination of authority and personalization. When a physician says "The majority of my patients in your situation start this therapy and manage it well," they are deploying a social norm — a descriptive proof point — through the channel the patient trusts most. This is qualitatively different from reading a patient testimonial on a pharmaceutical website, because the physician can tailor the social proof message to the individual patient's specific situation, concerns, and disease state.

[36][35]

- Cialdini's six principles — reciprocation, commitment, social proof, liking, authority, and scarcity — are extensively documented in pharmaceutical marketing literature. Physicians naturally embody the "authority" and "liking" principles, making their social proof messaging significantly more potent than the same message delivered through a marketing channel.
- A systematic review of social influence on health-related choices found that interpersonal influence — direct communication from a trusted person in the patient's network — consistently outperformed population-level messaging, including advertising, in driving actual behavior change.

- Peer-based social support programs (where patients connect with others on the same therapy) have demonstrated significant adherence improvements. In HIV research, the extent of peer social support was positively correlated with adherence to antiretroviral regimens. Physicians can initiate this effect by connecting new patients with peer resources — extending their educational influence beyond the clinical encounter.

> *Cialdini's Principle Applied: The physician simultaneously delivers authority ("my clinical recommendation"), social proof ("most patients manage this well"), and commitment ("I am counting on you to fill this today") — all in a single educational conversation. No marketing channel can replicate this combination.*

7.5 Social Marketing in Healthcare: Population-Level Lessons for Prescriber Education

Social marketing — the application of commercial marketing principles to drive behavior change for social benefit — has an established evidence base in healthcare. Its key principles parallel the physician education model in important ways: audience segmentation, message tailoring, barrier identification, channel selection, and feedback loops. Research published in Medical Decision Making confirmed that social marketing is an effective population-based behavior change strategy that can be applied in individual clinical settings, and that it is most effective when used to reinforce messages communicated at the population level.

[37]

The social marketing framework is instructive for designing physician education programs. Just as effective consumer marketing segments audiences and tailors messages to different psychographic profiles, effective physician education programs must acknowledge that patients come to the prescribing encounter with different activation levels, different emotional profiles, and different informational needs. A one-size-fits-all prescribing conversation leaves significant behavioral opportunity on the table.

Social marketing research also confirms the importance of what it calls "channel mix" — reaching the target audience through multiple reinforcing touchpoints. For therapy starts and adherence, the optimal channel mix is: physician education at the point of prescribing (highest trust, highest conversion), followed by extended at-home reinforcement (highest reach over time), with peer connection and digital engagement as supporting channels. This is precisely the model the clinical literature recommends — and it is also what marketing science would prescribe.

[37][31]

7.6 Digital Marketing and Outreach: Extending the Physician Voice

The fastest-growing body of marketing evidence relevant to therapy starts and adherence involves digital patient outreach — text messages, app-based education, telehealth follow-up, and physician-endorsed digital content. A 2023 study testing a text message outreach campaign for recently discharged patients found a 41% decline in 30-day hospital readmission risk among participants — a dramatic outcome driven by a channel that cost a fraction of traditional interventions.

[38][5]

The critical design principle revealed by the marketing research is that digital outreach is most effective when it is perceived as an extension of the physician relationship — not as a separate, branded patient support program. When patients receive a message that reads as coming from "your care team" or references their specific physician, it activates the same trust-driven adherence mechanism as the in-office encounter. When it reads as a branded pharmaceutical message, patients habituate to it and its behavioral impact diminishes rapidly.

This finding has direct strategic implications: manufacturer-sponsored patient support programs and digital engagement tools are most effective when they are designed to amplify the physician's voice, not to compete with it. The physician remains the primary behavioral driver; marketing infrastructure serves best when it reinforces and extends that relationship into the critical first 90 days of therapy.

[5][37]

> *Integrated Marketing Conclusion: Whether the lens is consumer psychology, behavioral economics, social marketing, or digital engagement research, the convergent finding is the same — the physician-patient educational relationship is the highest-fidelity, highest-conversion channel for driving therapy initiation and adherence. Every other marketing investment performs best when designed to support and extend it.*

Section 8: Extending the Education Moment — Clinic, Home, and Digital

8.1 The In-Clinic Encounter: The Foundation

The point-of-prescribing encounter is the highest-leverage educational moment, but it is also time-constrained. Research shows that the average specialty physician appointment lasts less than 20 minutes, and complex therapy counseling can easily crowd out other clinical priorities. Structured communication tools — including decision aids, visual aids, and abbreviated counseling checklists — have been shown to increase the efficiency and effectiveness of in-clinic educational encounters without adding significant time burden.

[18]

Embedding clinical pharmacists and patient navigators within specialty practices — as in the MIP model — effectively extends the educational capacity of the prescribing encounter without requiring additional physician time. These team-based approaches, explicitly endorsed by the CDC as a strategy for improving medication adherence, have demonstrated 15% higher adherence rates in the year following a hospital discharge compared to usual care.

8.2 At-Home Follow-Up: Reinforcing the Message in the Moment of Need

The most critical adherence window for complex therapies is the first 90 days — the period when most early discontinuation occurs, and when patient uncertainty and side effect-related anxiety peak. Physician-led or physician-initiated follow-up in this window — whether through telehealth, nurse calls scripted to the physician's guidance, or patient education materials developed with the physician's voice — has been shown to improve adherence rates substantially.

[5][6]

The JMIR 2022 field study found that mobile patient education systems that extended physician communication into the home — providing scheduled educational touchpoints aligned with the treatment journey — significantly increased patient trust and downstream adherence, using the same behavioral pathway model discussed in Section 2. The key design principle: the messaging must be perceived as physician-endorsed, not generic, for the trust-driven adherence mechanism to activate.

8.3 Combining In-Clinic and At-Home: The Multidisciplinary Advantage

The most robust adherence outcomes in the literature consistently come from programs that combine physician-led in-clinic education with structured at-home follow-up — a multidisciplinary model that treats the educational encounter as the beginning, not the entirety, of the patient support journey. A representative study in MS care found adherence of 89.3% in a multidisciplinary intervention group (pharmacist + neurologist + MS nurse + general practitioner) vs. 73.9% in usual care — a 15-point improvement driven by the combination of professional touchpoints, all anchored to the physician-patient relationship.

[14][6]

The evidence points to a clear hierarchy: physician-only education improves adherence; adding structured at-home educational follow-up multiplies the effect; combining both within a multidisciplinary team produces the highest and most durable adherence rates in the literature.

Section 9: Recommendations

For Pharmaceutical Manufacturers and Market Access Teams

- Invest in point-of-prescribing educational tools that enable and equip physicians to have cost, complexity, and commitment conversations at the moment of prescribing — before the patient reaches the pharmacy.
- Develop physician education programs that go beyond product information to build communication competency: how to set expectations, how to address hesitancy, and how to use SDM to increase patient commitment at initiation.
- Support and expand Medically Integrated Pharmacy-style models that embed clinical education capacity within the prescribing encounter, with demonstrated abandonment reduction from 18% to <1% in oncology.
- Fund academic detailing programs targeting high-prescribing physicians in key specialties, with structured educational curricula that improve both prescribing confidence and patient counseling quality.

For Health Systems and Specialty Practices

- Integrate real-time prescription benefits (RTPB) tools into EHR workflows to surface cost information at prescribing and prompt the physician-patient affordability conversation before abandonment can occur.
- Develop structured counseling protocols for complex therapy initiation — including patient-facing decision aids, side effect expectation-setting tools, and first-fill checklists — anchored to the prescribing encounter.
- Build team-based educational models that extend the physician's educational reach through embedded clinical pharmacists, nurse educators, and patient navigators aligned to the physician's guidance.

For Patient Engagement and Digital Health Teams

- Design digital patient education programs that are physician-endorsed and physician-voiced — creating a digital extension of the in-clinic encounter that preserves the trust-driven adherence mechanism.
- Time at-home educational touchpoints to the highest-risk abandonment windows: day 3 (first administration), day 7 (first week side effect experience), and day 30 (first refill decision).
- Use behavioral economics principles — commitment prompts, normalized framing of side effects, social norms language — in all patient-facing educational content developed in collaboration with physicians.

Conclusion

The evidence assembled in this white paper makes a clear, data-grounded case: the physician-patient educational encounter is the most powerful available intervention for improving therapy starts and sustaining long-term adherence in complex disease states. It is not the only intervention that works, but it is the intervention with the greatest effect size, the broadest applicability, and the deepest behavioral grounding.

A meta-analysis of 127 studies showed a 19% adherence improvement and a 1.62x odds ratio for adherence when physicians communicate well and are trained to do so. A single medically integrated pharmacy implementation reduced oral oncology abandonment from 18% to less than 1%. Ninety-one percent of psychiatric patients accepted complex injectable therapy when their physician led a structured educational conversation. A field study demonstrated that physician communication and trust explain 69.3% of the variance in actual patient adherence behavior.

These are not marginal findings. They represent the clearest signal in the adherence literature, and they point consistently to the same conclusion: when physicians educate their patients — at the point of prescribing, in the clinic, and through extended at-home touchpoints — patients start their therapies, stay on them, and achieve better outcomes.

The strategic and commercial imperative is equally clear. For any stakeholder — manufacturer, health system, payer, or patient advocacy organization — whose interests are served by higher therapy initiation and sustained adherence, investments in physician education capacity represent the highest-yield, most evidence-supported lever available.

> *The physician's recommendation is not just a clinical act. It is, in every meaningful sense, the most powerful patient education intervention available — and the data prove it.*

References

1. **Brigham and Women's Hospital / CVS Caremark (2010).** *Prescription cost and abandonment relationship.* Brigham and Women's Hospital Research.
2. **IQVIA (2020).** *Medicine Use and Spending in the U.S.: A Review of 2019 and Outlook to 2024.* IQVIA Institute for Human Data Science.
3. **Zolnierek, K.B. & DiMatteo, M.R. (2009).** *Physician Communication and Patient Adherence to Treatment: A Meta-Analysis.* Medical Care, 47(8), 826-834.
4. **DiMatteo, M.R. et al. (2002).** *Patient adherence and medical treatment outcomes: a meta-analysis.* Medical Care, 40(9), 794-811.
5. **Zhao, Y. et al. (2022).** *Patient Trust in Physicians Matters: Understanding the Role of a Mobile Patient Education System and Patient-Physician Communication in Improving Patient Adherence Behavior.* Journal of Medical Internet Research, 24(12).
6. **Kaniuka, A. et al. (2025).** *Enhancing Therapy Adherence: Impact on Clinical Outcomes, Healthcare Costs, and Patient Quality of Life*. MDPI Medicina, 61(1), 153.
7. **Texas Oncology / JCO Oncology Practice (2023).** *Impact of Medically Integrated Pharmacies on Oral Anticancer Medication Prescription Abandonment.* JCO Oncology Practice.
8. **Surescripts (2022).** *Surescripts Tackles Prescription Abandonment with Point-of-Care Information.* Surescripts Intelligence in Action.
9. **Siedlecki, S.L. et al. (2024).** *Assessment of the Utilization of Real-Time Prescription Benefits for Patient Cost Savings within an Outpatient Setting.* Research in Social and Administrative Pharmacy.
10. **Burnett, A. et al. (2020).** *An Ambulatory Care Clinic and Community Pharmacy Collaboration to Address Prescription Abandonment.* Journal of the American College of Clinical Pharmacy.
11. **Chen, W. et al. (2023).** *Impact of Pharmacist-Led PDCA Cycle in Reducing Prescription Abandonment: An Action Research from China.* Frontiers in Pharmacology.
12. **American Medical Association (2023).** *Prior Authorization Physician Survey Results.* AMA Annual Survey Report.
13. **Altamura, A.C. et al. (2020).** *The role of shared decision-making in improving adherence in schizophrenia: the PRELAPSE study.* PMC / Neuropsychiatric Disease and Treatment.
14. **Bermel, R. et al. (2019).** *Impact of Shared Decision Making on Disease-Modifying Drug Adherence in Multiple Sclerosis.* International Journal of MS Care / PMC.
15. **Winkeljohn, D. (2017).** *Effectiveness of a standardized patient education program on therapy-related side effects and unplanned therapy interruptions in oral cancer therapy: a cluster-randomized controlled trial.* Supportive Care in Cancer.
16. **Avorn, J. & Soumerai, S.B. (1983).** *Improving Drug-Therapy Decisions Through Educational Outreach (Academic Detailing) — A Randomized Controlled Trial.* New England Journal of Medicine, 308, 1457-1463.
17. **Grudniewicz, A. et al. (2015).** *Health care provider targeted interventions to improve medication adherence: systematic review and meta-analysis.* BMC Health Services Research.
18. **Joosten, E.A.G. et al. (2008).** *Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status.* Psychotherapy and Psychosomatics, 77(4).
19. **van Boven, J.F.M. et al. (2023).** *Shared decision making and medication adherence in patients with COPD and/or asthma: the ANANAS study.* Frontiers in Pharmacology.
20. **Kripalani, S. et al. (2007).** *Identification and Assessment of Adherence-Enhancing Interventions in Studies Assessing Medication Adherence Through Electronically Compiled Drug Dosing Histories.* Drugs.
21. **Rae-Grant, A. et al. (2018).** *Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis.* Neurology, 90(17).
22. **Giovannoni, G. et al. (2024).** *Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption.* Journal of Neurology.

23. **Terwee, C.B. et al. (2016).** *Patient-centered Outcomes of Medication Adherence Interventions: Systematic Review and Meta-Analysis.* Value in Health.
24. **Voshaar, M.J.H. et al. (2019).** *Effect of patient education on medication adherence of patients with rheumatoid arthritis: a randomized controlled trial.* Patient Education and Counseling.
25. **Brown, M.T. & Bussell, J.K. (2011).** *Medication Adherence: WHO Cares?.* Mayo Clinic Proceedings, 86(4).
26. **Orom, H. et al. (2018).** *Relationships as Medicine: Quality of the Physician-Patient Relationship Determines Physician Influence on Treatment Recommendation Adherence.* Journal of the American Board of Family Medicine.
27. **Schwartz, L.M. & Woloshin, S. (2019).** *Medical Marketing in the United States, 1997-2016.* JAMA, 321(1), 80-96.
28. **Liu, Q. & Gupta, S. (2023).** *Prescription Drug Advertising and Drug Utilization: The Role of Medicare Part D.* Journal of Public Economics / NBER Working Paper.
29. **Donohue, J.M. et al. (2004).** *Direct-to-Consumer Pharmaceutical Advertising and the Patient-Prescriber Encounter: A Systematic Review.* JAMA Internal Medicine / PMC.
30. **FDA (2004).** *Patient and Physician Attitudes and Behaviors Associated with DTC Promotion of Prescription Drugs.* U.S. Food and Drug Administration.
31. **Hibbard, J.H. et al. (2013).** *What the Evidence Shows About Patient Activation: Better Health Outcomes and Care Experiences; Fewer Data on Costs.* Health Affairs, 32(2).
32. **Hibbard, J.H. & Greene, J. (2013).** *When Patient Activation Levels Change, Health Outcomes and Costs Change, Too.* Health Affairs, 32(2).
33. **Dolan, N.C. et al. (2016).** *Learning from Marketing: Rapid Development of Medication Messages that Engage Patients.* PMC / Patient Education and Counseling.
34. **Cialdini, R.B. (1984).** *Influence: The Psychology of Persuasion.* HarperCollins (Revised Edition 2006).
35. **Lenz, A.S. et al. (2013).** *Peer Interventions to Promote Health: Conceptual Considerations.* American Journal of Health Studies / PMC.
36. **Sah, S. & Fugh-Berman, A. (2013).** *Physicians Under the Influence: Social Psychology and Industry Marketing Strategies.* Journal of Law, Medicine & Ethics.
37. **Evans, W.D. & McCormack, L. (2008).** *Applying Social Marketing in Health Care: Communicating Evidence to Change Consumer Behavior.* Medical Decision Making, 28(5).
38. **Bhatt, P. et al. (2023).** *Text Message Patient Outreach and Hospital Readmission Reduction.* JAMA Network Open.
39. **Shim, M. et al. (2024).** *Sources and Processes of Social Influence on Health-Related Choices: A Systematic Review.* Social Science & Medicine.

Appendix A: Summary of Key Research

The following table summarizes the primary research and evidence sources cited in this white paper, including publication details, study design, and key findings relevant to physician education, therapy starts, and adherence.

#	Authors / Org	Year	Study / Finding	Journal / Publication	Key Data Point
1	Brigham and Women's Hospital / CVS Caremark	2010	Prescription cost and abandonment relationship	Brigham and Women's Hospital Research	See body text
2	IQVIA	2020	Medicine Use and Spending in the U.S.: A Review of 2019 and Outlook to 2024	IQVIA Institute for Human Data Science	See body text
3	Zolnierek, K.B. & DiMatteo, M.R.	2009	Physician Communication and Patient Adherence to Treatment: A Meta-Analysis	Medical Care, 47(8), 826-834	See body text
4	DiMatteo, M.R. et al.	2002	Patient adherence and medical treatment outcomes: a meta-analysis	Medical Care, 40(9), 794-811	See body text
5	Zhao, Y. et al.	2022	Patient Trust in Physicians Matters: Understanding the Role of a Mobile Patient Education System and Patient-Physician Communication in Improving Patient Adherence Behavior	Journal of Medical Internet Research, 24(12)	See body text
6	Kaniuka, A. et al.	2025	Enhancing Therapy Adherence: Impact on Clinical Outcomes, Healthcare Costs, and Patient Quality of Life	MDPI Medicina, 61(1), 153	See body text
7	Texas Oncology / JCO Oncology Practice	2023	Impact of Medically Integrated Pharmacies on Oral Anticancer Medication Prescription Abandonment	JCO Oncology Practice	See body text
8	Surescripts	2022	Surescripts Tackles Prescription Abandonment with Point-of-Care Information	Surescripts Intelligence in Action	See body text
9	Siedlecki, S.L. et al.	2024	Assessment of the Utilization of Real-Time Prescription Benefits for Patient Cost Savings within an Outpatient Setting	Research in Social and Administrative Pharmacy	See body text
10	Burnett, A. et al.	2020	An Ambulatory Care Clinic and Community Pharmacy Collaboration to Address Prescription Abandonment	Journal of the American College of Clinical Pharmacy	See body text
11	Chen, W. et al.	2023	Impact of Pharmacist-Led PDCA Cycle in Reducing Prescription Abandonment: An Action Research from China	Frontiers in Pharmacology	See body text

#	Authors / Org	Year	Study / Finding	Journal / Publication	Key Data Point
12	American Medical Association	2023	Prior Authorization Physician Survey Results	AMA Annual Survey Report	See body text
13	Altamura, A.C. et al.	2020	The role of shared decision-making in improving adherence in schizophrenia: the PRELAPSE study	PMC / Neuropsychiatric Disease and Treatment	See body text
14	Bermel, R. et al.	2019	Impact of Shared Decision Making on Disease-Modifying Drug Adherence in Multiple Sclerosis	International Journal of MS Care / PMC	See body text
15	Winkeljohn, D.	2017	Effectiveness of a standardized patient education program on therapy-related side effects and unplanned therapy interruptions in oral cancer therapy: a cluster-randomized controlled trial	Supportive Care in Cancer	See body text
16	Avorn, J. & Soumerai, S.B.	1983	Improving Drug-Therapy Decisions Through Educational Outreach (Academic Detailing) — A Randomized Controlled Trial	New England Journal of Medicine, 308, 1457-1463	See body text
17	Grudniewicz, A. et al.	2015	Health care provider targeted interventions to improve medication adherence: systematic review and meta-analysis	BMC Health Services Research	See body text
18	Joosten, E.A.G. et al.	2008	Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status	Psychotherapy and Psychosomatics, 77(4)	See body text
19	van Boven, J.F.M. et al.	2023	Shared decision making and medication adherence in patients with COPD and/or asthma: the ANANAS study	Frontiers in Pharmacology	See body text
20	Kripalani, S. et al.	2007	Identification and Assessment of Adherence-Enhancing Interventions in Studies Assessing Medication Adherence Through Electronically Compiled Drug Dosing Histories	Drugs	See body text
21	Rae-Grant, A. et al.	2018	Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis	Neurology, 90(17)	See body text
22	Giovannoni, G. et al.	2024	Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption	Journal of Neurology	See body text

#	Authors / Org	Year	Study / Finding	Journal / Publication	Key Data Point
23	Terwee, C.B. et al.	2016	Patient-centered Outcomes of Medication Adherence Interventions: Systematic Review and Meta-Analysis	Value in Health	See body text
24	Voshaar, M.J.H. et al.	2019	Effect of patient education on medication adherence of patients with rheumatoid arthritis: a randomized controlled trial	Patient Education and Counseling	See body text
25	Brown, M.T. & Bussell, J.K.	2011	Medication Adherence: WHO Cares?	Mayo Clinic Proceedings, 86(4)	See body text
26	Orom, H. et al.	2018	Relationships as Medicine: Quality of the Physician-Patient Relationship Determines Physician Influence on Treatment Recommendation Adherence	Journal of the American Board of Family Medicine	See body text
27	Schwartz, L.M. & Woloshin, S.	2019	Medical Marketing in the United States, 1997-2016	JAMA, 321(1), 80-96	See body text
28	Liu, Q. & Gupta, S.	2023	Prescription Drug Advertising and Drug Utilization: The Role of Medicare Part D	Journal of Public Economics / NBER Working Paper	See body text
29	Donohue, J.M. et al.	2004	Direct-to-Consumer Pharmaceutical Advertising and the Patient-Prescriber Encounter: A Systematic Review	JAMA Internal Medicine / PMC	See body text
30	FDA	2004	Patient and Physician Attitudes and Behaviors Associated with DTC Promotion of Prescription Drugs	U.S. Food and Drug Administration	See body text
31	Hibbard, J.H. et al.	2013	What the Evidence Shows About Patient Activation: Better Health Outcomes and Care Experiences; Fewer Data on Costs	Health Affairs, 32(2)	See body text
32	Hibbard, J.H. & Greene, J.	2013	When Patient Activation Levels Change, Health Outcomes and Costs Change, Too	Health Affairs, 32(2)	See body text
33	Dolan, N.C. et al.	2016	Learning from Marketing: Rapid Development of Medication Messages that Engage Patients	PMC / Patient Education and Counseling	See body text
34	Cialdini, R.B.	1984	Influence: The Psychology of Persuasion	HarperCollins (Revised Edition 2006)	See body text
35	Lenz, A.S. et al.	2013	Peer Interventions to Promote Health: Conceptual Considerations	American Journal of Health Studies / PMC	See body text
36	Sah, S. & Fugh-Berman, A.	2013	Physicians Under the Influence: Social Psychology and Industry Marketing Strategies	Journal of Law, Medicine & Ethics	See body text

#	Authors / Org	Year	Study / Finding	Journal / Publication	Key Data Point
37	Evans, W.D. & McCormack, L.	2008	Applying Social Marketing in Health Care: Communicating Evidence to Change Consumer Behavior	Medical Decision Making, 28(5)	See body text
38	Bhatt, P. et al.	2023	Text Message Patient Outreach and Hospital Readmission Reduction	JAMA Network Open	See body text
39	Shim, M. et al.	2024	Sources and Processes of Social Influence on Health-Related Choices: A Systematic Review	Social Science & Medicine	See body text